{"id":"NCT01223352","sponsor":"Actelion","briefTitle":"Effects of Two Dosing Regimens of Bosentan in Children With Pulmonary Arterial Hypertension","officialTitle":"An Open-label, Prospective Multicenter Study to Assess the Pharmacokinetics, Tolerability, Safety and Efficacy of the Pediatric Formulation of Bosentan Two Versus Three Times a Day in Children With Pulmonary Arterial Hypertension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-03-08","primaryCompletion":"2013-04-03","completion":"2013-08-19","firstPosted":"2010-10-19","resultsPosted":"2017-06-29","lastUpdate":"2025-02-04"},"enrollment":64,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Pulmonary Arterial Hypertension"],"interventions":[{"type":"DRUG","name":"bosentan","otherNames":["Tracleer","ACT-050088"]}],"arms":[{"label":"Bosentan 2 mg/Kg t.i.d.","type":"EXPERIMENTAL"},{"label":"Bosentan 2 mg/Kg b.i.d.","type":"EXPERIMENTAL"}],"summary":"The primary objective of AC-052-373 was to assess the pharmacokinetic (PK) profile of two dosing regimens of the pediatric formulation of bosentan in children with pulmonary arterial hypertension (PAH) \\<12 years of age.","primaryOutcome":{"measure":"Dose-corrected Daily Exposure [AUC(0-24c)] to Bosentan","timeFrame":"0, 0.5, 1, 3, 5 (or 7.5), 8 (or 12 hours) post-dose at Week 4, after at least 2 weeks of stable study drug treatment","effectByArm":[{"arm":"Bosentan 2 mg/kg t.i.d. (PK Set)","deltaMin":7275.1,"sd":null},{"arm":"Bosentan 2 mg/kg b.i.d. (PK Set)","deltaMin":8535.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"3 Months","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":31},"commonTop":["UPPER RESPIRATORY TRACT INFECTION","PYREXIA","NASOPHARYNGITIS","DIARRHOEA","VOMITING"]}}